San Antonio Breast Cancer Symposium | Conference

Kevin Kalinsky, MD, MS, on Next Steps Following the Phase 3 RxPONDER Trial
January 20, 2021

Investigators aimed to evaluate additional end points from the phase 3 RxPONDER trial in women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer.

Kevin Kalinsky, MD, MS, on the RxPONDER Trial Methods
January 18, 2021

In this trial, investigators launched RxPONDER, in which 5015 patients with a recurrence score between 0 and 25 were randomized to endocrine therapy alone or chemotherapy followed by endocrine therapy.

Kevin Kalinsky, MD, MS, on the Aim of the Phase 3 RxPONDER Trial in Breast Cancer Subtype
January 13, 2021

A recent study sought to evaluate the 21-gene Oncotype Dx Recurrence Score in nonmetastatic HR-positive, HER2-negative breast cancer.